TCL Archive “Too much [of NCI’s] planning is reactive rather than proactive. As a consequence, vision suffers.” July 7, 1995
TCL Archive ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay July 17, 2009
TCL Archive Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review January 12, 1979
TCL Archive SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma September 29, 2006
